PSYENCE GROUP INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 CAD | +20.00% |
|
+50.00% | -40.00% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed ISO22000 facility in Southern Africa. The Companyâs divisions include Psyence Production, Psyence Therapeutics and Psyence Function. Psyence Therapeutics develops natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Production operates federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world. Psyence Function is focused on the development, distribution and sale of over-the-counter functional mushroom nutraceutical products.
Calendar
2024-06-06
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 3.05M | |
| +3.13% | 43.43B | |
| +48.71% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +1.58% | 12.33B | |
| +32.83% | 12.59B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- PSYG Stock
- News Psyence Group Inc.
- Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
